TM-CYFRA 21-1

The TM-CYFRA 21-1 ELISA is an enzyme immunoassay for measurement of CYFRA21-1 in serum and heparin plasma


Catalog No Size
Product Catalog No: EIA-5070 Pack Size: 96 Wells

Pack Size:
Pack Size:
Pack Size:
Pack Size:

Category:
Test Principle

The TM-CYFRA 21-1 ELISA Kit is a solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. The microtiter wells are coated with a monoclonal [mouse] antibody directed towards a unique antigenic site of the CYFRA21-1 molecule. An aliquot of sample containing endogenous CYFRA21-1 is incubated in the coated well with enzyme conjugate, which is an anti- CYFRA21-1 monoclonal antibody conjugated with horseradish peroxidase. After incubation the unbound conjugate is washed off. The amount of bound peroxidase is proportional to the concentration of CYFRA21-1 in the sample. Having added the substrate solution, the intensity of colour developed is proportional to the concentration of CYFRA21-1 in the sample

Order Enquiry

Order Enquiry Form

References
  • Rastel D. et al. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group. Eur. J. Cancer; 1994; 30A(5); 601-6.
  • Wieskopf B., et al. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest; 1995; 108(1); 163-9.
  • Farlow E.C. et al. A multi-analyte serum test for the detection of non-small cell lung cancer. Br. J. Cancer; 2010; 103(8); 1221-8.
  • Molina R. et al. Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol.; 2008; 29(6); 371-80.
  • Tomita M. et al. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. Anticancer Res.; 2010; 30(7); 3099-102.
  • Pujol J.L. et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Brit. J. Cancer; 2004; 90(11); 2097-2105.
  • Muley T., Dienemann H., Ebert W. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in pstage I NSCLC. Anticancer Res. 2003; 23(5b); 4085-93.
  • Holdenrieder S., et al. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer; 2009; 63(1); 128-35.
  • Yamamoto K. et al. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer; 1997; 1;79(9); 1647-55.
  • Andreadis C. et al. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy. J. Urol.; 2005; 174(5); 1771-5.
Enquiry